Japanese drug company Eisai‘s (TYO:4523) bid to extend the patent life of its blockbuster Alzheimer’s drug Aricept with a new skin patch formulation has been dealt a blow by the U.S. Food and Drug Administration. Eisai’s drug partner Teikoku Pharma has received a complete response letter from the FDA stating that the agency cannot approve […]
North Carolina pharmaceutical company Pozen (NASDAQ:POZN) and drug partner AstraZeneca (NYSE:AZN) are taking legal action to block a generic competitor to osteoarthritis drug Vimovo. The companies have filed a patent infringement lawsuit in U.S. District Court for the District of New Jersey against India-based generics company Dr. Reddy’s Laboratories (NYSE:RDY). Dr. Reddy’s notified both companies […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Salix Pharmaceuticals (NASDAQ:SLXP) is still working through issues that kept regulators from approving a drug for irritable bowel syndrome, but the North Carolina company is securing additional patent rights on the compound for other indications. Morrisville, North Carolina-based Salix announced Wednesday that the U.S. Patent and Trade Office has issued three patents relating to rifaximin, […]
There are many exciting legislative and regulatory changes on the horizon relating to patents. As you have probably been hearing, President Obama is throwing his support behind these major changes as they promote job creation and economic growth. Now, the words “exciting” and “legislative/regulatory” are not usually used in the same sentence, but with the […]
Generic competition to Pozen’s (NASDAQ:POZN) migraine drug Treximet will be held at bay for now. A judge in the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction that orders Par Pharmaceutical (NYSE:PRX) not to make or sell a generic version of Treximet, which is sold in the United States […]
Two dry eye therapy patents owned by Inspire Pharmaceuticals (NASDAQ:ISPH) have received extensions in Japan, which gives the drug Diquas patent protection until February 2023. Raleigh, North Carolina-based Inspire disclosed in a securities filing that the extension gives one Diquas patent an additional five years of exclusivity; another patent received approximately 4.5 years of exclusivity. […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A federal judge in California dealt blows to both sides in a patent infringement dispute over spinal implant technology between several Medtronic Inc. (NYSE:MDT) subsidiaries and NuVasive Inc. (NSDQ:NUVA). Judge Michael Anello of the U.S. District Court for Southern California “tentatively” denied Medtronic’s move for summary judgment “on the ground that there are no genuine […]
North Carolina pharmaceutical company BioDelivery Sciences International has extended its patent in Canada by 10 years, giving additional protection for the company’s core drug delivery technology. Raleigh, North Carolina based BDSI’s (NASDAQ:BDSI) drug delivery technology releases medicine to a patient via a small piece of dissolvable film placed on the inside of the cheek. BDSI […]
A patent dispute involving three makers of new innovative medical devices - Bovie Medical, Salient Surgical and Medtronic - has forced Bovie to pull its Seer and Boss monopolar and bipolar saline-enhanced radio-frequency devices off the market to settle the dispute.
Going once... going twice... SOLD! The mechanical stress technology goes to the gentleman with the brown hat in the second row. These days, you can auction off baseball cards, Olympic gold medals, even Elvis' hair. So I guess it shouldn't be surprising to see neurostimulation technology on the block.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
It hasn't attracted much attention yet, but a case making its way through federal court to a sure-fire date with the U.S. Supreme Court could obliterate the business models of biotech companies across the country. The case, which pits the American Civil Liberties Union against Myriad Genetics & Laboratories, concerns whether Myriad can hold patents over two genes, BRCA1 and BRCA2, which the company uses to diagnose women with ovarian and breast cancer.
Need a Deep Web Miner to retrieve hard-to-find life sciences research? How about a cell therapy manufacturing system? A self-coiling surgical tool? Then Battelle might have the intellectual property for you.
Google Health seems to have been stuck in neutral almost from the start, Chilmark Research writes. But rumors of its death may be exaggerated, according to The Health Care Blog.
Highlights of the important and the interesting from the world of healthcare: Is Cisco’s tablet an “iPad killer” for healthcare? Aiming for the business market while the iPad seems more of a consumer device, Cisco unveiled its Cius tablet, which is scheduled for release early next year. The always-insightful mobihealth news speculates that the Cius, […]
(With updates with what other blogs are saying; see below): The Supreme Court issued a unanimous and somewhat surprising decision limiting the scope of business methods patents. The ruling in In Re Bilski upheld a lower court decision that invalidated two inventors’ patent on a method of hedging weather-related risk in energy prices. The high […]